These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 3492224)

  • 1. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.
    Press OW; Appelbaum F; Ledbetter JA; Martin PJ; Zarling J; Kidd P; Thomas ED
    Blood; 1987 Feb; 69(2):584-91. PubMed ID: 3492224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies.
    Hu E; Epstein AL; Naeve GS; Gill I; Martin S; Sherrod A; Nichols P; Chen D; Mazumder A; Levine AM
    Hematol Oncol; 1989; 7(2):155-66. PubMed ID: 2784122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
    Press OW; Eary JF; Badger CC; Martin PJ; Appelbaum FR; Levy R; Miller R; Brown S; Nelp WB; Krohn KA
    J Clin Oncol; 1989 Aug; 7(8):1027-38. PubMed ID: 2666588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
    Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
    Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody T101 in T cell malignancies: a clinical, pharmacokinetic, and immunologic correlation.
    Bertram JH; Gill PS; Levine AM; Boquiren D; Hoffman FM; Meyer P; Mitchell MS
    Blood; 1986 Sep; 68(3):752-61. PubMed ID: 3488778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
    Maloney DG; Liles TM; Czerwinski DK; Waldichuk C; Rosenberg J; Grillo-Lopez A; Levy R
    Blood; 1994 Oct; 84(8):2457-66. PubMed ID: 7522629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
    Pagel JM; Hedin N; Subbiah K; Meyer D; Mallet R; Axworthy D; Theodore LJ; Wilbur DS; Matthews DC; Press OW
    Blood; 2003 Mar; 101(6):2340-8. PubMed ID: 12446461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
    Press OW; Eary JF; Appelbaum FR; Martin PJ; Badger CC; Nelp WB; Glenn S; Butchko G; Fisher D; Porter B
    N Engl J Med; 1993 Oct; 329(17):1219-24. PubMed ID: 7692295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience.
    Johnson TA; Press OW
    Ann Hematol; 2000 Apr; 79(4):175-82. PubMed ID: 10834504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody.
    Parker BA; Vassos AB; Halpern SE; Miller RA; Hupf H; Amox DG; Simoni JL; Starr RJ; Green MR; Royston I
    Cancer Res; 1990 Feb; 50(3 Suppl):1022s-1028s. PubMed ID: 2297715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
    Pagel JM; Lin Y; Hedin N; Pantelias A; Axworthy D; Stone D; Hamlin DK; Wilbur DS; Press OW
    Blood; 2006 Jul; 108(1):328-36. PubMed ID: 16556891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.
    Lauria F; Lenoci M; Annino L; Raspadori D; Marotta G; Bocchia M; Forconi F; Gentili S; La Manda M; Marconcini S; Tozzi M; Baldini L; Zinzani PL; Foà R
    Haematologica; 2001 Oct; 86(10):1046-50. PubMed ID: 11602410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.
    Press OW; Corcoran M; Subbiah K; Hamlin DK; Wilbur DS; Johnson T; Theodore L; Yau E; Mallett R; Meyer DL; Axworthy D
    Blood; 2001 Oct; 98(8):2535-43. PubMed ID: 11588052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.
    Green DJ; Shadman M; Jones JC; Frayo SL; Kenoyer AL; Hylarides MD; Hamlin DK; Wilbur DS; Balkan ER; Lin Y; Miller BW; Frost SH; Gopal AK; Orozco JJ; Gooley TA; Laird KL; Till BG; Bäck T; Sandmaier BM; Pagel JM; Press OW
    Blood; 2015 Mar; 125(13):2111-9. PubMed ID: 25628467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome.
    Benkerrou M; Jais JP; Leblond V; Durandy A; Sutton L; Bordigoni P; Garnier JL; Le Bidois J; Le Deist F; Blanche S; Fischer A
    Blood; 1998 Nov; 92(9):3137-47. PubMed ID: 9787149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
    Press OW; Farr AG; Borroz KI; Anderson SK; Martin PJ
    Cancer Res; 1989 Sep; 49(17):4906-12. PubMed ID: 2667754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
    Tobinai K; Kobayashi Y; Narabayashi M; Ogura M; Kagami Y; Morishima Y; Ohtsu T; Igarashi T; Sasaki Y; Kinoshita T; Murate T
    Ann Oncol; 1998 May; 9(5):527-34. PubMed ID: 9653494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
    Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
    Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
    Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.
    Huhn D; von Schilling C; Wilhelm M; Ho AD; Hallek M; Kuse R; Knauf W; Riedel U; Hinke A; Srock S; Serke S; Peschel C; Emmerich B;
    Blood; 2001 Sep; 98(5):1326-31. PubMed ID: 11520778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.